688658.SH
悦康药业
SSE · Healthcare · Biotechnology · CN
CNY 13.21
−7.69%Aug 20, 2026, 10:41 UTC
Yuekang Pharmaceutical announced it will invest 45 million yuan of excess raised funds into a small nucleic acid drug R&D project, covering three investigational drugs.
Source:Aug 20, 2026, 10:41 UTC
Yuekang Pharmaceutical announced its first-half 2026 results, reporting a net loss attributable to shareholders of 105 million yuan, compared with a loss of 98.8291 million yuan in the same period last year.
Source:Aug 5, 2026, 09:12 UTC
Yuekang Pharmaceutical received NMPA approval to conduct clinical trials for its YKYY017 nebulized inhalation agent with a new indication for treating and preventing respiratory infections related to human coronavirus OC43 (HCoV-OC43).
Aug 4, 2026, 09:18 UTC
Yuekang Pharmaceutical: Controlling shareholder's 1.8847 million shares unfrozen, all shares now unfrozen.